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Background: The growth of solid tumors and their regrowth after treatment is dependent upon functional tumor
vasculature. Some chemotherapeutic agents have shown anti-angiogenic properties but there are limited studies of
the effect of chemotherapy on tumor vasculature. Here we investigate the effect of paclitaxel, 5-fluorouracil (5-FU)
and doxorubicin on tumor vasculature in subcutaneous and orthotopic xenografts in mice.
Methods: The vascular density and percentage of functional blood vessels were evaluated in subcutaneous A431
human vulvar cancer xenografts, and in subcutaneous and orthotopic MCF-7 human breast cancer xenografts,
following single doses of paclitaxel, 5-FU or doxorubicin.
Results: There was no significant difference in total (CD31+) blood vessels between untreated ectopic and orthotopic
MCF-7 tumors, but there was a significantly lower proportion of functional blood vessels in orthotopic tumors. After
paclitaxel treatment, there was a decrease in functional tumor vasculature in A431 subcutaneous xenografts, followed
by a subsequent rebound. There was a significant decrease in total vascular density on day 12 in A431 tumors following
5-FU or doxorubicin treatment, but no change in the percentage of functional vessels. An increase in functional blood
vessels or percentage of functional vasculature was noted in MCF-7 subcutaneous and orthotopic xenografts following
chemotherapy treatment.
Conclusions: There are differences in the vasculature and microenvironment of ectopic and orthotopic xenografts
in mice. Anti-tumor effects of chemotherapy may be due, in part, to effects on tumor vasculature and may vary
in different tumor models.
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The presence of functional vasculature within solid tu-
mors is required to provide sufficient nutrients and
oxygenation to tumor cells, and is therefore essential
for the growth of solid tumors and for their repopula-
tion after treatment [1]. Adequate drug distribution
within solid tumors is also dependent on functional
vasculature. Therefore, evaluating the ability of various
chemotherapeutic treatments to alter tumor vascula-
ture has important implications for understanding the
effects of treatment.* Correspondence: ian.tannock@uhn.ca
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unless otherwise stated.Angiogenesis, the formation of new blood vessels, oc-
curs through a delicate balance between pro- and anti-
angiogenic factors, such as VEGF and thrombospondin-1,
respectively [2,3]. Given the dependence of tumor growth
on tumor vascularity, numerous studies have focused on
targeting the process of angiogenesis. Drugs targeted
against the vascular endothelial growth factor (VEGF)
pathway, such as bevacizumab, are being utilized in the
clinic [4]. However, data suggest that other anti-cancer
agents, including chemotherapy and targeted agents such
as EGFR inhibitors, might also have effects to decrease the
quantity or functionality of tumor vasculature [5-10].
A few studies have shown that taxanes, such as pacli-
taxel and docetaxel, can inhibit endothelial cell prolifera-
tion in vitro, and have vascular disrupting propertieshis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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treated tumors [5-8]. Shaked et al. showed that pacli-
taxel, docetaxel, and 5-FU all caused a decrease in
microvascular density and a corresponding increase in
the recruitment of circulating endothelial progenitors
(CEPs), which might contribute to vascular rebound fol-
lowing treatment, whereas, gemcitabine, cisplatin, and
doxorubicin did not have an effect on vascular density
or circulating endothelial progenitors [9]. Metronomic
chemotherapy (i.e. chemotherapy administered at lower
doses at more frequent intervals) has also shown antian-
giogenic properties through increased endothelial cell
apoptosis [11-17].
Various tumor models are utilized to investigate the
efficacy of anti-cancer therapies. Ectopic tumor xeno-
grafts are often used to assess antitumor activity of
cytotoxic or cytostatic agents due to the reproducibility
and ease of access of this tumor model when evaluating
tumor growth [18]. However, studies suggest that orthoto-
pic tumors (i.e. tumor cells implanted at the site of origin)
are more similar to clinical tumors due to the establish-
ment of a heterogeneous tumor microenvironment, the
expression of biologically relevant growth factor receptors
and proteins, and the metastatic potential of tumor cells
to spread to distant sites, thereby reflecting the natural
course of clinical cancers [18,19]. Studies by Fidler and
colleagues have shown that the expression of multidrug
resistance genes and proteins can differ depending on
the organ environment, thereby altering the efficacy of
chemotherapy against tumors implanted at different
organ sites [20-22]. These studies highlight the effect of
the organ environment on tumor growth and response
to therapy; therefore, it is important to determine
whether different organ sites might also impact the
tumor vasculature and microenvironment.
The present study aims to investigate whether the
commonly used anticancer drugs paclitaxel, 5-FU, and
doxorubicin modify the functional vasculature of sub-
cutaneous A431 xenografts, and of subcutaneous or
orthotopic MCF-7 xenografts.Methods
Cell lines
Experiments were performed using the vulvar epidermoid
carcinoma cell line A431, and the breast carcinoma cell
line MCF-7. All cells were purchased from the American
Type Culture Collection (ATCC; Manassas, VA). A431
cells were maintained in Dulbecco’s Modified Eagle’s
Medium supplemented with 10% fetal bovine serum (FBS;
Hyclone, Logan, UT). MCF-7 cells were grown in α-MEM
with 10% FBS. All media was obtained from the hospital
media facility. Cells were grown in a humidified atmos-
phere of 95% air and 5% CO2 at 37°C. Routine tests toconfirm cell line origin, and to exclude mycoplasma were
performed.
Drugs and reagents
Paclitaxel, 5-FU and doxorubicin were standard clinical
formulations purchased from the hospital pharmacy, and
were diluted in PBS. DiOC7 was purchased from AnaSpec
Inc. (San Jose, CA) and a stock solution (2.5 mg/mL) was
made by dissolving DiOC7 powder in DMSO. The stock
was diluted 1:10 in PBS and 10% Solutol HS 15.
Effect of paclitaxel, 5-FU and doxorubicin on tumor
vasculature
Female athymic nude mice (4 to 6 weeks old) (Harlan
Sprague-Dawley (HSD), Madison, WI) were injected
subcutaneously on both flanks with 1×106 A431 cells or
4×106 MCF-7 cells per side to generate xenografts. Prior
to injection of MCF-7 cells, mice were implanted with
17β estradiol tablets (60 day release; Innovative Research
of America, Sarasota, FL). For orthotopic tumors, 1×106
MCF-7 cells (suspended in Matrigel) were injected into
the mammary fat pads of 4-6 week old female athymic
nude mice (HSD). Two perpendicular diameters were
measured with a calliper and when tumors grew to a
diameter of 5-8 mm, mice were treated with a single
dose of paclitaxel (25 mg/kg i.p.), 5-FU (100 mg/kg i.p.)
or doxorubicin (8 mg/kg i.v.).
Tumor samples were taken on days 0, 2, 4, 8 and 12
following administration of the chemotherapy drug.
The perfusion marker DiOC7 (1 mg/kg) was injected
intravenously 1 minute prior to killing the mice. Tu-
mors were excised, immersed in OCT compound and
frozen in liquid nitrogen. Tumors were cut into 10 μm
sections and imaged using an Olympus BX50 fluores-
cence microscope.
Tumor sections were first imaged for the perfusion
marker DiOC7 using a FITC filter set. Sections were
then stained for blood vessels using antibodies specific
for the endothelial cell marker CD31 [rat anti-CD31
primary antibody (1:100); BD Biosciences, and Cy3-
conjugated goat anti-rat IgG secondary antibody
(1:400)]. Tumor sections were imaged for CD31 using
the Cy3 (530-560 nm excitation/573-647 nm emission)
filter set.
Image analysis and quantification
Microscope images of tumor vasculature were quantified
using Media Cybernetics Image Pro PLUS software. A
threshold was used to select pixels occupied by blood
vessels, as represented by CD31 staining, and the image
was binarised by setting these blood vessel regions to
white (pixel value 255) and background pixels to black
(pixel value 0) to form a “mask” of positive CD31 stain-
ing. Using Image Pro’s Count/Size tool, objects with a
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in each tumor section. The tumor area was measured by
drawing an ‘Area of Interest’ around tumor regions on
the image (excluding areas of necrosis or artefacts) using
Image Pro’s calibrated area measurement tool. The mean
number of total blood vessels per tumor area was calcu-
lated. A similar method was used to evaluate functional
blood vessels: the total number of objects in DiOC7
binarised images was counted and the number of
DiOC7-positive objects was divided by the number of
CD31-positive objects to provide an estimate of the pro-
portion of functional vessels in each tumor section.
Statistical analysis
For analysis of total and functional tumor vasculature, t-
tests were performed to determine significant differences
between groups. P < 0.05 was used to indicate statistical
significance; all tests were 2-sided.
Animal ethics statement
Animal experiments were carried out using protocol
(AUP #1232.15) approved by the University Health Net-
work (UHN) Animal Care Committee under the guide-
lines of the Canadian Council on Animal Care.
Results
Effect of chemotherapy on tumor size in A431 and MCF-7
xenografts
Mice were treated with a single dose of paclitaxel, doxo-
rubicin, or 5-FU. Dose response studies were previously
completed in the laboratory, and the dose of each
chemotherapy agent was chosen based on optimal anti-
tumor effect with minimal toxicity as determined by
measurement of body weight (data not shown). Tumor
size was measured by calculating the pixel area occupied
by the tumor (Table 1). Untreated (Day 0) MCF-7 xeno-
grafts were larger in size compared to A431 xenografts.
There was no significant difference in the tumor size of
untreated ectopic and orthotopic tumors. The tumor
area of Day 12 A431 xenografts treated with paclitaxel
was significantly smaller than control tumors (P = 0.03);Table 1 Tumor area as measured by number of pixels (x107) f
xenografts taken on Day 0 (untreated), 2, 4, 8, or 12 followin
(DOX 8 mg/kg, i.v.), or 5-FU (100 mg/kg, i.p.)
Day A431 MCF-7 Paclitaxel
Paclitaxel DOX 5-FU SC O
0 1.18 (0.27) 2.29 (0.25) 2.29 (0.25) 4.79 (0.65) 7.
2 ______ 2.43 (0.38) 1.96 (0.19) ______ 3.
4 1.67 (0.16) 2.70 (0.49) 2.71 (0.49) 3.94 (0.61) 5.
8 0.99 (0.15) 2.42 (0.36) 1.92 (0.32) 3.78 (0.47) 5.
12 0.47 (0.06)* 2.11 (0.47) 1.27 (0.37) 4.57 (0.33) 2.
Symbols (*) represent statistically significant differences in tumor area compared tohowever, there was no significant change in tumor size
in A431 xenografts treated with doxorubicin or 5-FU.
There was no difference in tumor area of ectopic and
subcutaneous MCF-7 xenografts treated with paclitaxel
or doxorubicin (all time points). Subcutaneous MCF-7
xenografts taken on Day 4 following 5-FU treatment had
a significantly smaller tumor area compared to control
tumors (P = 0.001); there was no difference in tumor size
in ectopic MCF-7 xenografts treated with 5-FU.
Effect of various chemotherapy drugs on tumor
vasculature in A431 xenografts
There was a significant decrease in the total (CD31+)
and functional (DiOC7+) blood vessels on days 4 and
12, and on days 4, 8, and 12, respectively, following a
single dose of paclitaxel (P < 0.05). A decrease in the per-
centage of functional tumor vasculature was also noted
in A431 xenografts on days 4 and 8 following a single
dose of paclitaxel compared to untreated (day 0) tumors;
this was followed by a subsequent increase in the per-
centage of functional blood vessels back to pre-
treatment levels by day 12 (Figure 1A).
There was a significant decrease in the total (CD31+)
blood vessels per unit area in day 12 tumors compared
to untreated tumors following doxorubicin treatment
(Figure 1B, P = 0.04). A significant decrease in vascular
density was also noted in A431 tumors taken on day 2,
4, 8, and 12 following treatment with 5-FU when com-
pared to controls (Figure 1C, P < 0.05). However, there
was no significant change in the percentage of functional
blood vessels present in A431 xenografts treated with 5-
FU (100 mg/kg) or doxorubicin (8 mg/kg) (Figure 1B
and C, P > 0.05).
Differences in tumor vasculature in ectopic versus
orthotopic MCF-7 tumors
The vascular density (CD31+ blood vessels per tumor
area) was not significantly different between ectopic and
orthotopic MCF-7 tumors. However, there was a signifi-
cantly lower number of functional (DiOC7+) blood ves-
sels, and a lower percentage of functional vasculature inor A431 xenografts, and ectopic or orthotopic MCF-7
g a single dose of paclitaxel (25 mg/kg, i.p.), doxorubicin
MCF-7 DOX MCF-7 5-FU
rtho SC Ortho SC Ortho
40 (4.60) 4.79 (0.65) 7.40 (4.60) 4.79 (0.65) 7.40 (4.60)
25 (1.41) 6.99 (0.91) 2.53 (0.55) 7.27 (1.16) 5.34 (1.24)
04 (1.41) 4.86 (1.33) 3.29 (—) 1.27 (0.53)* 4.49 (2.08)
20 (0.80) 3.39 (0.63) 4.06 (1.35) 5.11 (1.17) 5.85 (0.76)
05 (0.82) 3.17 (0.65) ______ 3.34 (0.85) 7.48 (0.83)
control tumors (P < 0.05).
Figure 1 The number of total (CD31+) and functional (DiOC7+) blood vessels per tumor area (left panels), and the percentage of
functional blood vessels (right panels) present on Day 0, 2, 4, 8, and 12 in A431 xenografts following a single dose of A) paclitaxel
(25 mg/kg, i.p.), B) doxorubicin (8 mg/kg, i.v.), or C) 5-FU (100 mg/kg, i.p.). Bars represent the mean of 5-6 tumors; error bars represent
standard error of the mean (SEM). Symbols represent statistical significance for total (*), functional (♦), and percent functional (+) blood vessels as
compared to control (Day 0) tumors.
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ectopic tumors grown subcutaneously (Figure 2, P < 0.05).
Ectopic MCF-7 tumors taken on Day 8 or 12 following
chemotherapy treatment were compared to orthotopic
MCF-7 tumors from the same time point to determine if
there were any differences in vascular density, number of
functional vessels, or percentage of functional bloodvessels. There was no difference in tumor vasculature be-
tween ectopic and orthotopic MCF-7 tumors treated with
paclitaxel (Figure 3C). A significantly lower number of
functional blood vessels (DiOC7+) were noted in orthoto-
pic tumors on Day 8 following doxorubicin treatment
when compared to ectopic tumors (Figure 4C, P = 0.008).
Orthotopic MCF-7 xenografts treated with 5-FU had a
Figure 2 The number of total (CD31+) and functional (DiOC7+) blood vessels (per tumor area), and the percentage of functional blood
vessels present in untreated MCF-7 subcutaneous or orthotopic xenografts. Bars represent the mean of 2-12 tumors; error bars represent
standard error of the mean (SEM). Scale – numeric values represent number of blood vessels per unit area (x106) for the left and middle panels,
and percent functional blood vessels for the right panel. Symbols represent statistical significance between subcutaneous and orthotopic tumors
for functional (*) and percent functional (♦) blood vessels.
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tional (DiOC7+) blood vessels, and a lower percentage of
functional vessels (Figure 5C, P < 0.01) on Day 12 after
treatment.
Effect of paclitaxel on tumor vasculature in subcutaneous
(ectopic) and orthotopic MCF-7 xenografts
A decrease in the number of functional blood vessels
(DiOC7+ vessels per unit area) was noted on day 4 and
8 following treatment of subcutaneous (ectopic) MCF-7
xenografts with a single dose of paclitaxel (Figure 3A,
P < 0.05) and there was a significant decrease in total
(CD31+) blood vessels on day 12 compared to control
tumors (P = 0.03). There was no significant difference
in the percentage of functional vasculature in ectopic
MCF-7 xenografts taken on days 2-12 following a single
dose of paclitaxel when compared to untreated tumors
(Figure 3A, P > 0.05). Conversely, there was an increase
in the number of functional (DiOC7+) blood vessels
and the percentage of functional vasculature in orthotopic
MCF-7 tumors on day 4 compared to control (Figure 3B,
P < 0.05); however, there was no significant change in the
total (CD31+) tumor vasculature with paclitaxel treatment
in orthotopic tumors.
Effect of doxorubicin on tumor vasculature in
subcutaneous and orthotopic MCF-7 xenografts
There was no significant difference in the total (CD31+)
or functional (DiOC7+) vascular density in MCF-7 ectopic
or orthotopic tumors following doxorubicin treatment.On day 2 following doxorubicin treatment there was a de-
crease in the percentage of functional blood vessels in sub-
cutaneous MCF-7 xenografts, although this was not a
significant change (P > 0.05); there was a subsequent re-
bound in the functional vasculature back to control levels
by day 8 (Figure 4A). There was a significant increase in
the percentage of functional tumor vasculature in both
day 12 ectopic and day 8 orthotopic tumors, respectively,
when compared to controls (Figure 4A and B, P < 0.01 and
P = 0.04, respectively).Effect of 5-fluorouracil (5-FU) on tumor vasculature in
subcutaneous and orthotopic MCF-7 xenografts
There was a significant increase in the functional
(DiOC7+) vascular density and percentage of functional
blood vessels noted in subcutaneous MCF-7 xenografts
on day 12 following 5-FU treatment compared to un-
treated tumors (Figure 5A, P < 0.01 respectively); how-
ever, there was no difference in total vascular density
(CD31+) following 5-FU treatment (Figure 5A, P > 0.05).
In the orthotopic MCF-7 xenografts, there was a sig-
nificant increase in the functional (DiOC7+) blood ves-
sels in tumors taken on days 2 and 4 compared to
controls, as well as an increase in the percentage of
functional vasculature noted in day 2 and 8 tumors
compared to controls (Figure 5B, P < 0.05); there was
no significant change in the total (CD31+) vascular
density following 5-FU treatment of orthotopic MCF-7
tumors (Figure 5B, P > 0.05).
Figure 3 Effect of paclitaxel on tumor vasculature in MCF-7 xenografts. The number of total (CD31+) and functional (DiOC7+) blood vessels per
tumor area (left panels), and the percentage of functional blood vessels (right panels) present on Day 0, 2, 4, 8, and 12 in MCF-7 A) subcutaneous
xenografts or B) orthotopic xenografts following a single dose of paclitaxel (25 mg/kg, administered intraperitoneally). C) The number of total (CD31+)
and functional (DiOC7+) blood vessels (per tumor area), and the percentage of functional blood vessels present in Day 12 MCF-7 subcutaneous or
orthotopic xenografts. Bars represent the mean of 2-12 tumors; error bars represent standard error of the mean (SEM). Symbols represent statistical
significance for total (*), functional (♦) and percent functional (+) blood vessels as compared to control (Day 0) tumors.
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The growth of solid tumors and their repopulation after
treatment are dependent upon functional tumor vascula-
ture; however, the delivery of anti-cancer therapies alsorequires proper vascular architecture within a solid tumor
[23-27]. Given the complex interactions of chemotherapy
with the tumor microenvironment and tumor vascula-
ture, we aimed to investigate the effects of paclitaxel,
Figure 4 Effect of doxorubicin on tumor vasculature in MCF-7 xenografts. The number of total (CD31+) and functional (DiOC7+) blood vessels per
tumor area (left panels), and the percentage of functional blood vessels (right panels) present on Day 0, 2, 4, 8, and 12 in MCF-7 A) subcutaneous
xenografts or B) orthotopic xenografts following a single dose of doxorubicin (8 mg/kg, administered intravenously). C) The number of total (CD31+) and
functional (DiOC7+) blood vessels (per tumor area), and the percentage of functional blood vessels present in Day 12 MCF-7 subcutaneous or orthotopic
xenografts. Bars represent the mean of 2-6 tumors; error bars represent standard error of the mean (SEM). Symbols represent statistical significance for
percent functional blood vessels (+) as compared to control (Day 0) tumors, and significance between subcutaneous and orthotopic tumors (●).
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including a comparison of subcutaneous and orthotopic
MCF-7 xenografts.
Tumor models such as subcutaneous and orthotopic
xenografts grown in nude mice have long been used in
the investigation of the efficacy of anti-cancer agents.Studies have highlighted the importance of organ spe-
cific environments in the development of biologically
heterogeneous tumors that more closely mimic the clin-
ical progression of solid tumors and possess a similar
metastatic potential [18,19]. Furthermore, tumors grown
orthotopically have been shown to respond differently to
Figure 5 Effect of 5-fluorouracil on tumor vasculature in MCF-7 xenografts. The number of total (CD31+) and functional (DiOC7+) blood vessels
per tumor area (left panels), and the percentage of functional blood vessels (right panels) present on Day 0, 2, 4, 8, and 12 in MCF-7 A) subcutaneous
xenografts or B) orthotopic xenografts following a single dose of 5-fluorouracil, 5-FU (100 mg/kg, administered intraperitoneally). C) The
number of total (CD31+) and functional (DiOC7+) blood vessels (per tumor area), and the percentage of functional blood vessels present in
Day 12 MCF-7 subcutaneous or orthotopic xenografts. Bars represent the mean of 2-6 tumors; error bars represent standard error of the mean
(SEM). Symbols represent statistical significance for functional and percent functional (+) blood vessels as compared to control (Day 0)
tumors, and significance between subcutaneous and orthotopic tumors.
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[20-22]. However, few studies have investigated differences
in the tumor microenvironment between ectopic andorthotropic xenografts and there are limited data on the
effect of chemotherapeutic agents to alter tumor vascula-
ture in these models.
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density in untreated ectopic versus orthotopic MCF-7
tumors but there were fewer functional blood vessels
(DiOC7+ per tumor area) in orthotopic MCF-7 tumors
(Figure 2). A study by Ho et al. showed higher vascular
density in orthotopic breast tumors compared to sub-
cutaneous tumors of similar size [28], but the CD31
endothelial marker was utilized in their study, which
makes it difficult to ascertain whether there was a simi-
lar difference in functional vasculature. Our study uti-
lizes the perfusion marker DiOC7 in addition to CD31
to evaluate changes in the functional blood vessels, and
highlights the importance of quantifying both total and
functional vasculature.
Our observation of an initial decrease in the percent-
age of functional blood vessels following treatment of
subcutaneous A431 and MCF-7 xenografts with pacli-
taxel (Figures 1A and 3A) agrees with previous studies
showing decreased vascular density following treatment
of experimental tumors with taxanes [5-8]. Interest-
ingly, we found no significant effect of paclitaxel on the
functional tumor vasculature in orthotopic tumors
(Figure 3B).
A series of studies by Fidler and colleagues showed
that colon carcinoma tumors grown subcutaneously had
a greater anti-tumor response to doxorubicin compared
to orthotopic tumors, whereas they showed a compar-
able response to 5-FU. Analysis of different organ sites
showed differential expression of mdr genes, which in-
fluence response to doxorubicin but not to 5-FU
[18,20-22]. In the present study, subcutaneous and
orthotopic MCF-7 xenografts treated with either doxo-
rubicin or 5-FU, and orthotopic tumors treated with
paclitaxel showed a delayed increase in the percentage
of functional blood vessels despite similar tumor sizes
in treated tumors compared to controls (Table 1;
Figures 3B, 4 and 5). Previous studies have demon-
strated anti-angiogenic properties of taxanes, through
targeting of cycling endothelial cells [5-8]; however,
Shaked et al. showed that chemotherapeutic agents
such as taxanes and 5-FU also initiate a systemic re-
sponse leading to the recruitment of circulating endo-
thelial progenitors (CEPs), which stimulate the process
of angiogenesis [9]. Increases in functional vasculature
noted in our study following chemotherapy treatment
in MCF-7 tumors could be related to recruitment of
CEPs or to changes in the tumor microenvironment,
including changes in interstitial fluid pressure or
normalization of tumor vasculature following chemo-
therapy [29,30]. Interestingly, there was a significantly
lower number of total (CD31+) and functional (DiOC7+)
blood vessels, as well as a lower percentage of functional
vasculature, in orthotopic MCF-7 tumors taken on Day 12
following 5-FU treatment as compared to ectopic(subcutaneous) MCF-7 xenografts (Figure 5C, P < 0.01).
Perhaps differences in the tumor microenvironment, re-
cruitment of CEPs, or differential gene expression be-
tween different organ sites in which orthotopic and
ectopic tumors are grown, might have contributed to the
lack of rebound in tumor vasculature noted in orthotopic
tumors following 5-FU treatment.
A strength and novelty of the current study is that
both total and functional vasculature were characterized
through the utilization of a flow marker in addition to
immunohistochemical staining for total (CD31+) blood
vessels in order to compare the differences in vasculature
in different tumor models (ectopic versus orthotopic xe-
nografts) following treatment with various chemotherapy
agents. We observed different effects of chemotherapy on
total and functional vasculature, thus emphasizing the im-
portance of analyzing changes in functional vasculature.
The current study also highlights the importance of the
organ environment when choosing tumor models. A
major weakness of the present study is that blood vessels
in transplanted tumors, independent of site of transplant-
ation, are derived from the host and may not reflect those
in a spontaneous tumor. However, orthotopic tumors ap-
pear to more closely represent the clinical course of can-
cer progression when compared to ectopic tumors, and
our data suggest that utilization of orthotopic tumor
models might be more appropriate when using trans-
planted tumors in determining clinical effects of anti-
cancer treatments.Conclusions
The present study shows that there are differences in the
vasculature and tumor microenvironment of ectopic and
orthotopic xenografts in mice. Anti-tumor effects of
chemotherapy may be due, in part, to effects on tumor
vasculature and may vary in different tumor models.
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